RxDoctor Payments Data

Kelly Toups, APRN

Family · Shreveport, LANPI 1912976614

Payments from drug & device makers

$1,555in general payments, 2019–2025

Across 27 payments — averaging $57.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$455
  • Novo Nordisk$389
  • AstraZeneca$202
  • Boston Scientific$199
  • AbbVie$171
  • GSK$44
  • plus $95 from 4 others

What the payments were for

  • Food & beverage$1,555100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott6$455
Novo Nordisk4$389
AstraZeneca2$202
Boston Scientific3$199
AbbVie4$171
GSK2$44
Lilly USA, LLC2$37
Pfizer2$27
Exact Sciences1$16
Gilead1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,555 in reported general payments places this provider in the 70th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$48,778
Medicare patients
170
Services billed
799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$107,769
JanuviaSitagliptin Phosphate23$34,914
JardianceEmpagliflozin22$33,225
MounjaroTirzepatide20$30,103
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$26,612
TrulicityDulaglutide15$25,006
FarxigaDapagliflozin Propanediol21$16,100
EliquisApixaban11$13,557
Aimovig AutoinjectorErenumab-Aooe13$9,301
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$5,971
Albuterol Sulfate HfaAlbuterol Sulfate67$1,973
Metoprolol Succinate127$1,719
Rosuvastatin Calcium137$1,663
Ultra-Fine Short Pen NeedlePen Needle, Diabetic12$1,414
Atorvastatin Calcium223$1,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$389$107,76982 claims
Lilly USA, LLCMounjaro, Trulicity$37$55,10835 claims
GSKTrelegy Ellipta$44$26,61236 claims
AstraZenecaFarxiga$202$16,10021 claims
PfizerEliquis$27$13,55711 claims
AbbVieSynthroid$171$51714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,610 family providers in Louisiana.

Other family in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →